Recombinant Human IL-1ra/IL-1F3 Biotinylated Protein, CF

Biotinylated Recombinant Human IL‑1ra/IL‑1F3 Protein (Catalog # BT280) binds Recombinant Human IL-1 RI Fc Chimera (11085-RI) with an ED50 of 0.350-4.20 ng/mL.

2 μg/lane of Biotinylated Recombinant Human IL‑1ra/IL‑1F3 Protein (Catalog # BT280) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 18-23 kDa, under reducing conditions.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human IL-1ra/IL-1F3 Biotinylated Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA.

  Biotinylated Recombinant Human IL-1ra/IL-1F3 (Catalog # BT280) binds Recombinant Human IL-1 RI Fc Chimera (Catalog # 11085-RI) with an ED₅₀ of 0.350-4.20 ng/mL.

• Source: E. coli-derived human IL-1ra/IL-1F3 protein
• Accession #: P18510
• Structure / Form: Biotinylated via amines
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 17 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 18-23 kDa, under reducing conditions.

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining
• Reconstitution Instructions: Reconstitute at 250 μg/mL in water.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human IL-1ra/IL-1F3 Biotinylated Protein, CF

• DIRA
• ICIL-1ra
• IL1F3
• IL-1F3
• IL1ra
• IL-1ra
• IL-1ra3
• IL1RN
• IL-1RN
• interleukin 1 receptor antagonist
• IRAP
• MVCD4

Background

IL-1ra was originally isolated from the urine of patients with monocytic leukemia and has also been purified from adherent monocytes. The naturally occurring, fully glycosylated form has an apparent molecular weight of about 25,000 Daltons. The protein shows 26% amino acid homology to IL-1 beta and 19% homology to IL-1 alpha . It will compete with either factor for receptor binding, but does not interact with either one. Human IL-1ra will bind to both types of IL-1 receptor (I and II) on human cells, but reportedly will not block binding to the type II receptor on murine pre-B cell lines. The recombinant, non-glycosylated form of IL-1ra blocks binding of IL-1 to its receptor equally as well as the naturally-occurring, glycosylated form. The IL-1ra has been shown to block the inflammatory responses induced by IL-1 both in vitro and in vivo. Currently, pre-clinical and clinical studies are underway to test possible therapeutic applications for IL-1ra in the treatment of sepsis, rheumatoid arthritis and chronic myelogenous leukemia.

Bioinformatics

• Uniprot:
  • P18510()